News
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: TUI delivers strong preliminary FY 2025 results above expectations with underlying EBIT growth of +12.6% exceeding guidance of +9-11% at constant currency
TUI AG delivers strong preliminary FY 2025 results with underlying EBIT growth of +12.6%, exceeding guidance of +9-11% at constant currency. Record performance in Hotels & Resorts and Cruises -
COMMUNIQUÉ DE PRESSE
SANY Heavy Industry's 'Three Transformation' Strategy Boosts Growth: Q3 Revenue Surges by 10.73%
SANY Heavy Industry reports Q3 revenue surged by 10.73% to $2.96 billion, driven by 'Three Transformation' strategy focused on globalization, digitalization, and low-carbon development -
COMMUNIQUÉ DE PRESSE
Loar Holdings Inc. Reports Q3 2025 Record Results and Upward Revisions to 2025 Outlook and Full Year 2026 Outlook
Loar Holdings Inc. reports record Q3 2025 results with $126.8M net sales, $27.6M net income, and raised 2025 & 2026 outlook. CEO Dirkson Charles comments on the strong performance in commercial aviation and defense markets -
COMMUNIQUÉ DE PRESSE
Epanko Expansion Supports EcoGraf HFfree® Downstream Facilities
-
-
COMMUNIQUÉ DE PRESSE
Fineqia Cross-Lists Bitcoin Yield ETP (YBTC) and FTSE Cardano Enhanced Yield ETN (YADA) on gettex
Fineqia cross-lists Bitcoin Yield ETP and FTSE Cardano Enhanced Yield ETN on gettex, Munich Stock Exchange, for European investors with DeFi opportunities. CFO Warren Sergeant discusses benefits -
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
New data from Telomir Pharmaceuticals show Telomir-1 effectively modulates iron levels in human keratinocytes, key for its epigenetic mechanism. Telomir-1 provides strong intracellular iron reduction surpassing Deferoxamine
